Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BrainCool AB (publ) (BRAIN.ST)
Lund, SE
BrainCool AB (publ), a medical technology company founded in 2010 and headquartered in Lund, Sweden, focuses on the development, commercialization, and distribution of advanced medical cooling systems. Operating with its subsidiaries, the company caters to the healthcare sector, primarily serving the Swedish market, by providing innovative solutions for various conditions including stroke, sudden cardiac arrest, oral mucositis, and migraine. Their product line features the BrainCool and RhinoChill systems, specifically engineered to deliver swift therapeutic cooling in emergency situations, thereby ensuring uninterrupted patient care. To mitigate the risk of oral mucositis, BrainCool offers the Cooral system, renowned for its user-friendly design for medical professionals. Furthermore, the IQool system boasts an intuitive interface complemented by informative graphics and an automatic feedback loop, empowering clinicians to dedicate their attention to patient management rather than device operation.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.27% | +3.87% | -2.85% | +50.95% | +40.02% | +25.38% | -53.35% | -57.33% | -89.61% | -92.74% | -68.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-9.4% Q1'26: -3.7% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+11.8% Q1'26: +37.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-155.3% Q1'26: -159.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-95.1% Q1'26: -86.7% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-25.3% Q1'26: -30.9% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q1'26: +55.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.00× Q1'26: 0.00× (vs Q1'25)
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|
| Revenue |
36.21M
est: 45.00M (-19.5%)
|
41.00M
41.00M – 41.00M
-8.9% YoY
|
48.00M
48.00M – 48.00M
+17.1% YoY
|
58.00M
58.00M – 58.00M
+20.8% YoY
|
| EBITDA |
-29.99M
est: -42.12M (+28.8%)
|
-38.38M
-38.38M – -38.38M
+8.9% YoY
|
-44.93M
-44.93M – -44.93M
-17.1% YoY
|
-54.29M
-54.29M – -54.29M
-20.8% YoY
|
| EBIT |
-34.43M
est: -43.85M (+21.5%)
|
-39.95M
-39.95M – -39.95M
+8.9% YoY
|
-46.77M
-46.77M – -46.77M
-17.1% YoY
|
-56.51M
-56.51M – -56.51M
-20.8% YoY
|
| Net Income |
-37.05M
est: -27.87M (-32.9%)
|
-25.34M
-25.34M – -25.34M
+9.1% YoY
|
-5.07M
-5.07M – -5.07M
+80.0% YoY
|
-2.53M
-2.53M – -2.53M
+50.0% YoY
|
| SGA |
2.0K
est: 27.03M (-100.0%)
|
24.62M
24.62M – 24.62M
-8.9% YoY
|
28.83M
28.83M – 28.83M
+17.1% YoY
|
34.83M
34.83M – 34.83M
+20.8% YoY
|
| EPS |
-0.15
est: -0.11 (-36.4%)
|
-0.10
-0.10 – -0.10
+9.1% YoY
|
-0.02
-0.02 – -0.02
+80.0% YoY
|
-0.01
-0.01 – -0.01
+50.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Anna Lindstrom | Chief Executive Officer | — | female |
| Christian Strand | Head of Distribution & Sales | — | male |
| Jimmy Hedenstjerna | Chief Technology Officer | — | male |
| Jon Berg | Chief Operating Officer | — | male |
| Lotta Valfridsson | Chief Financial Officer | — | female |
| Mohammad Fazel | Head of Clinical Studies | — | male |
| Oscar Engellau | Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BRAIN.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
